

Pfizer Oncology Posters and Oral Presentations

February 17-19, 2022



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

In accordance with ASCO guidelines, ASCO GU presentations can be accessed on the ASCO GU Congress site.

Pfizer Oral Presentations

Oral presentations will be presented in Pacific Standard Time (PST).

Oral Abstract Session A: Prostate Cancer

Thursday, February 17

1:42 PM – 1:52 PM PST

Enzalutamide

15

A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE

Merseburger A

Presentation is supported by Pfizer and Astellas Pharma Inc.

[View Presentation](#)

Pfizer Poster Sessions

Poster presentations will be presented in Pacific Standard Time (PST).

Poster Session A: Prostate Cancer

Thursday, February 17

11:30 AM – 1:00 PM PST

Enzalutamide

20

Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapy-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA)

Morgans A

Presentation is supported by Pfizer and Astellas Pharma Inc.

[View Presentation](#)

Enzalutamide

115

Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or *de novo* mHSPC (M1 at diagnosis): *Post hoc* analysis of the phase 3 ARCHES trial

Armstrong A

Presentation is supported by Pfizer and Astellas Pharma Inc.

[View Presentation](#)

Enzalutamide

183

Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty

Swami U

Presentation is supported by Pfizer and Astellas Pharma Inc.

[View Presentation](#)

Relugolix

101

Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study

Shore N

Presentation is supported by Pfizer and Myovant.

[View Presentation](#)

Relugolix

104

Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study

Tutrone R

Presentation is supported by Pfizer and Myovant.

[View Presentation](#)

Relugolix

105

Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide

George D

Presentation is supported by Pfizer and Myovant.

[View Presentation](#)

Talazoparib

52

Treatment (tx) patterns among men with metastatic castration resistant prostate cancer (mCRPC) in the United States (US)

Barata P

[View Presentation](#)

Talazoparib

66

Treatment trends among men with metastatic castration sensitive prostate cancer (mCSPC): Results from the US component of an international study

Barata P

[View Presentation](#)

Talazoparib

157

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity

Dorff T

[View Presentation](#)

Trials in Progress Poster Session A: Prostate Cancer

Thursday, February 17

11:30 AM – 1:00 PM PST

Relugolix

TPS207

Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study

De La Cerda J

Presentation is supported by Pfizer and Myovant.

[View Presentation](#)

Talazoparib

TPS221

Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

Agarwal N

Acknowledgments: This study is sponsored by Pfizer. Astellas Pharma Inc. provided enzalutamide.

[View Presentation](#)

Poster Session B: Urothelial Carcinoma

Friday, February 18

12:30 PM – 2:00 PM PST

Avelumab

456

Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study

Gupta S

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Avelumab

457

Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5)

Milloy N

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Avelumab

486

Avelumab first-line (1L) maintenance + best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis

Eto M

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Avelumab

487

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial

Powles T

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Trials In Progress Poster Session B: Urothelial Carcinoma

Friday, February 18

12:30 PM – 2:00 PM PST

Avelumab

TPS578

PATRIOT II: An ambispective, observational, multicenter, 2-cohort of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States

Grivas P

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Saturday, February 19

7:00 AM – 8:00 AM PST

Avelumab

301

Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the United Kingdom

Nathan P

Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)

Axitinib

314

Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

Zakharia Y

[View Presentation](#)

Axitinib

315

Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population

Strambi A

[View Presentation](#)